Document Detail


Letrozole for ovulation induction and controlled ovarian hyperstimulation.
MedLine Citation:
PMID:  20592587     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Letrozole, an aromatase inhibitor, is the newest addition to our armamentarium in the treatment of infertility. It is utilized in much the same way as clomiphene citrate, but with some additional benefits. In this review, the latest studies will be summarized with emphasis on dose, duration of use, safety, number of mature follicles, and pregnancy outcomes. RECENT FINDINGS: Letrozole has fewer side effects, and a shorter half-life than clomiphene citrate, and no demonstrable effect upon the receptivity of the endometrium. It is efficacious in treating women with chronic anovulation, unexplained infertility and diminished ovarian reserve. Its safety is superior to clomiphene citrate. Utilizing bio-equivalent doses, letrozole pregnancy rates are equal or superior to clomiphene citrate. Several studies suggest situations where it is more efficacious than gonadotropin treatment. SUMMARY: With further study, this drug could replace clomiphene citrate as the primary medication for chronic anovulation and/or unexplained infertility. It could augment or even obviate the use of gonadotropins in the treatment of women who have been unsuccessful in achieving pregnancy with clomiphene citrate. It may also be an adjunct for women with diminished ovarian reserve. Further studies are needed to determine optimal dosing and long term safety for women treated with the drug.
Authors:
Elizabeth A Pritts
Related Documents :
400717 - Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despit...
15870557 - Is laparoscopy necessary before assisted reproductive technology?
16530767 - Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndr...
1915947 - The gonadotropin-releasing hormone agonist stimulation test--a sensitive predictor of p...
1519497 - A new zealand randomized comparative study of three iuds (nova-t, mlcu375, mlagcu250): ...
1251027 - Compliance characteristics of angiographic guidewires.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in obstetrics & gynecology     Volume:  22     ISSN:  1473-656X     ISO Abbreviation:  Curr. Opin. Obstet. Gynecol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-08     Completed Date:  2010-10-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007264     Medline TA:  Curr Opin Obstet Gynecol     Country:  England    
Other Details:
Languages:  eng     Pagination:  289-94     Citation Subset:  IM    
Affiliation:
Wisconsin Fertility Institute, Middleton, Wisconsin 53562, USA. lapskyboy@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anovulation / drug therapy*
Aromatase Inhibitors / administration & dosage*
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Nitriles / administration & dosage*
Ovulation Induction / methods*
Triazoles / administration & dosage*
Chemical
Reg. No./Substance:
0/Aromatase Inhibitors; 0/Nitriles; 0/Triazoles; 112809-51-5/letrozole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Right ventricular function by strain echocardiography.
Next Document:  Principles and strategies for dealing with complications in laparoscopy.